Company Profile
Viatris Inc. Stock Price, News & Analysis
- Ticker:
- VTRS
- Exchange:
- NASDAQ
- Sector:
- Generics, Small Molecule Drugs
- Location:
- United States
Stock performance
16.29 USD (-7.71%)
Close
Last updated: August 6, 2026
18.3B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, VTRS closed down 7.71% at $16.29. No new same-company headline was identified in the current news window.
Company overview
Business overview
Viatris is a global healthcare company formed from the combination of Mylan and Pfizer’s Upjohn business. Its portfolio spans generics, branded generics, and some specialty products, with a business model centered on scale and portfolio management.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Viatris has a global commercial footprint. It sits in generics and diversified pharmaceuticals rather than biotech.
Business Model Characteristics
The company generates value through product volume, geographic breadth, and lifecycle management across a broad medicines portfolio. Investors watch margin discipline, product mix, and the company’s ability to stabilize revenue after the merger integration.
Position Within the Biotechnology Landscape
Viatris is outside biotech and closer to diversified pharma and generics. It matters to healthcare investors because its products are broadly used, but it is not a catalyst-heavy biotech stock.
Future catalysts
Viatris’s near-term catalysts are biosimilar launches, portfolio simplification, and continued debt / capital-allocation progress. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label than about whether the platform can keep producing credible next steps.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Viatris Inc. (VTRS)?
Viatris Inc. (VTRS) most recently closed at 16.29 USD, a -7.71% move versus the previous session.
What is the market cap of Viatris Inc. (VTRS)?
Viatris Inc. currently has a market capitalization of 18.3B USD on BioPharmSignal.
What does Viatris Inc. do?
Viatris is a global healthcare company formed from the combination of Mylan and Pfizer’s Upjohn business. Its portfolio spans generics, branded generics, and some specialty products, with a business model centered on scale and portfolio management.
On which exchange is VTRS stock listed?
Viatris Inc. (VTRS) is associated with NASDAQ, United States, Generics, Small Molecule Drugs.
What is Viatris?
Viatris’s near-term catalysts are biosimilar launches, portfolio simplification, and continued debt / capital-allocation progress.
Which conditions is Viatris Inc. targeting with Viatris?
Viatris’s near-term catalysts are biosimilar launches, portfolio simplification, and continued debt / capital-allocation progress.
How does Viatris Inc. describe recent progress with Viatris?
Viatris’s near-term catalysts are biosimilar launches, portfolio simplification, and continued debt / capital-allocation progress.
What is Mylan?
Viatris is a global healthcare company formed from the combination of Mylan and Pfizer’s Upjohn business.